Unique Functional and Structural Properties of the LRRK2 Protein ATP-binding Pocket-Reference-Cited by-同舟云学术

Unique Functional and Structural Properties of the LRRK2 Protein ATP-binding Pocket

Published:2014-11 Issue:47 Volume:289 Page:32937-32951
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Liu Zhiyong,Galemmo Robert A.,Fraser Kyle B.,Moehle Mark S.,Sen Saurabh,Volpicelli-Daley Laura A.,DeLucas Lawrence J.,Ross Larry J.,Valiyaveettil Jacob,Moukha-Chafiq Omar,Pathak Ashish K.,Ananthan Subramaniam,Kezar Hollis,White E.Lucile,Gupta Vandana,Maddry Joseph A.,Suto Mark J.,West Andrew B.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference45 articles.

1. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology;Zimprich;Neuron,2004

2. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease;Paisán-Ruíz;Neuron,2004

3. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity;West;Proc. Natl. Acad. Sci. U.S.A,2005

4. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity;Jaleel;Biochem. J,2007

5. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease;Cookson;Nat. Rev. Neurosci,2010

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LRRK2 Kinase Inhibitor PF-06447475 Protects Drosophila melanogaster against Paraquat-Induced Locomotor Impairment, Life Span Reduction, and Oxidative Stress;Neurochemical Research;2024-06-07

2. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson’s disease;Bioorganic Chemistry;2024-02

3. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson’s disease;Bioorganic Chemistry;2023-12

4. Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives;European Journal of Medicinal Chemistry;2023-08

5. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson’s Disease;Medicinal Chemistry;2022-08